Serological response rates in subgroups of patients with B-NHL. (A) The percentage of seropositive patients in each of the B-NHL patient subgroups: post treatment (patients who completed anti-CD20 Ab containing therapy >6 months before vaccination), active treatment (patients who are under current anti-CD20 Ab therapy or that completed treatment up to 6 months before vaccination), and treatment naïve (patients with i-B-NHL under watch-and-wait management), compared with healthy controls. (B) Shown are titer levels in each of the B-NHL patient subgroups and in healthy controls.